Hematology
News from the FDA/CDC
CDC panel backs mRNA COVID vaccines over J&J because of clot risk
The risk of dying from TTS after a Johnson & Johnson shot is extremely rare.
From the Journals
Antithrombotic therapy not warranted in COVID-19 outpatients
In stable patients with COVID-19, use of aspirin or apixaban did not reduce the rate of the composite of all-cause mortality, thromboembolism, MI...
From the Journals
Sickle cell disease, trait may up risk for poor COVID outcomes
Even those who carry just one copy of the sickle cell gene – the carrier status for sickle cell disease – appeared to be at heightened risk.
From the Journals
Infusion centers may best EDs for treating sickle cell crises
At infusion centers, patients received pain medication an average of 70 minutes faster compared with patients treated in EDs.
From the Journals
Reversal agents curb DOAC-related bleeding but deaths still high
The meta-analysis of more than 4,000 patients also showed thrombotic events were more frequent with andexanet than with 4PCC or idarucizumab.
Conference Coverage
Omics analysis links blood type to COVID-19
News
How some COVID-19 vaccines could cause rare blood clots
Six cases of a rare but serious event in patients who got the J&J vaccine are being reviewed.
From the Journals
Novel antiplatelet drug: Hope for efficacy without bleeding?
A new antiplatelet drug with a completely novel mechanism of action could hold the promise of delivering the holy grail – reducing cardiac events...
Conference Coverage
What to do when anticoagulation fails cancer patients
Feature
CMS launches hospital-at-home program to free up hospital capacity
The agency will be giving more flexibility to ambulatory surgery centers (ASCs) to provide hospital-level care.
Conference Coverage
Factor XI inhibitor–based anticoagulation strategies gain ground
“When we compare the FXI inhibitors with existing anticoagulants, we don’t necessarily want to go up against the DOACs.”